Medtronic Announces CE Mark of Evolut ™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe

The system includes 4 valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest annular range (for self-expanding TAVI technology) on the market. The approval follows a recent indication expansion for the Evolut platform in Europe for patients with severe aortic stenosis who are at a low risk of surgical mortality and patients with bicuspid aortic valves who are at intermediate, high and extreme risk of surgical mortality.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news